- Case Report
- Open Access
Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature
BMC Research Notes volume 6, Article number: 450 (2013)
Bevacizumab, a recombinant humanized monoclonal antibody for vascular endothelial growth factor, has been widely used in various cancers offering substantial clinical benefit. It is reportedly associated with development of high-grade proteinuria and nephrotic syndrome with the histology of thrombotic microangiopathy, but there has been no report describing the development of immunoglobulin A nephropathy in bevacizumab-treated patients.
A 68-year-old man with metastatic rectal cancer was treated with bevacizumab. He presented with hematuria and proteinuria 15 and 17 months, respectively, after bevacizumab initiation. Bevacizumab was stopped at 17 months. Renal biopsy at 19 months revealed immunoglobulin A nephropathy, with numerous paramesangial hemispherical deposits and thrombotic microangiopathy. Electron microscopy showed numerous paramesangial electron-dense deposits of various sizes, and subendothelial injuries. Proteinuria almost completely resolved 8 months after bevacizumab cessation, although hematuria persisted. Follow-up renal biopsy 11 months after bevacizumab cessation showed a marked decrease in mesangial immunoglobulin A deposits and paramesangial electron-dense deposits, which correlated with a gradual decrease in serum immunoglobulin A.
This is the first case report that confirmed histologically the development and resolution of immunoglobulin A nephropathy during and after bevacizumab therapy. This case shows that there may be other mechanisms of glomerular injury by bevacizumab besides glomerular endothelial injury leading to thrombotic microangiopathy.
Vascular endothelial growth factor (VEGF) is an endogenous glycoprotein that plays a critical role in the growth of blood vessels . Bevacizumab, a recombinant humanized monoclonal antibody for VEGF, inhibits tumor angiogenesis, and the addition of bevacizumab to chemotherapy is effective in the treatment of advanced or metastatic cancers, including breast cancer, colorectal cancer, and non-small cell lung cancer, renal cell carcinoma, and glioblastoma multiforme . However, the addition of bevacizumab to chemotherapy increases the risk of high-grade proteinuria and nephrotic syndrome . Eremina et al. reported that thrombotic microangiopathy (TMA) was common in patients treated with bevacizumab and that, in human renal biopsy specimens and an animal model, a decrease in glomerular VEGF induced direct damage of the glomerular endothelium.
We describe the case of a patient with metastatic rectal cancer treated with bevacizumab, who developed nephrotic syndrome with the histology of immunoglobulin (Ig) A nephropathy with massive paramesangial deposits, along with mild TMA. Proteinuria resolved following bevacizumab cessation, and marked decreases in both IgA and paramesangial electron-dense deposits (EDDs) were confirmed by follow-up biopsy 11 months after bevacizumab cessation.
A 68-year-old man with no remarkable medical history underwent rectal low anterior resection in November 2008 for Stage T3N0M0 rectal cancer. In December 2009, pulmonary metastasis was found and capecitabine, oxaliplatin, and bevacizumab treatment (400 mg every 3 weeks) initiated. At chemotherapy initiation, his serum creatinine was 0.66 mg/dl. Urinalysis was done every month after the initiation of chemotherapy, but neither proteinuria nor hematuria was evident. In March 2011 (15 months after chemotherapy initiation), dipstick urine evaluation first demonstrated hematuria of 1–2+. Proteinuria was evident for 2 months afterward. Subsequently, chemotherapy was stopped at the end of May 2011. However, heavy proteinuria persisted, and the patient was referred to us in July 2011. He had gained 6 kg of body weight and had developed edema of the lower extremities over the preceding month. His blood pressure was 135/80 mm Hg. Laboratory investigations are listed in Table 1. Urinalysis showed proteinuria of 3.5 g/day and >100 red blood cells/high-power field (HPF), with granular and fatty casts. Marked hypoproteinemia and hypoalbuminemia were observed, but serum creatinine was normal. Serum IgA was elevated to 487 mg/dl (normal: 110–410 mg/dl). Serum complement component (C) 3 and C4, total serum hemolytic activity, and hepatobiliary function were normal. Tests for hepatitis B and C, antinuclear antibody, anti–double-stranded deoxyribonucleic acid antibody, and cryoglobulins were all negative. Carcinoembryonic antigen (CEA) was elevated to 11.5 ng/ml (normal: <5 ng/ml), but carbohydrate antigen 19–9 was within normal range. No red blood cell fragmentation was observed. Computed tomography showed normal-sized kidneys, massive ascites, and bilateral pleural effusion, and a small, isolated pulmonary metastatic lesion was observed in the right inferior lobe.
Percutaneous renal biopsy was performed. Three out of forty-three glomeruli were globally sclerotic. Other glomeruli exhibited mild-to-moderate mesangial proliferation, with periodic acid-Schiff (PAS)-positive paramesangial hemispherical deposits. Capillary lumens were dilated and occupied by PAS-positive material. Mesangiolysis was also observed in some glomeruli (Figures 1A and B). Tubular atrophic and interstitial fibrotic changes were observed focally. Arterial vessels showed mild sclerosis, with no intra-arterial or intra-arteriolar thrombi. Immunofluorescence (IF) study revealed marked intensity (+++) for IgA (Figure 1C) and C3, and slight intensity (+) for IgG, IgM, C1q, and fibrinogen, which were found mainly in the mesangium and along capillary walls. Electron microscopy revealed numerous EDDs in paramesangial areas, which were fine granular, spherical, or hemispherical in shape and varying in size (Figure 2A). Similar EDDs were observed in some subendothelial areas. In addition, subendothelial electron-lucent widening with loose granular materials was observed focally and segmentally. Some glomerular capillary lumens were occupied with globular and loose materials, which were thought to be serum components. These materials gathered in subendothelial areas, compressing endothelial cells to the opposite side (Figure 2B).
The patient underwent follow-up for nephrotic syndrome with unremarkable therapy. Heavy proteinuria with hematuria continued after bevacizumab cessation, but began to decrease gradually after 6 months. Eight months later, proteinuria had decreased to 0.3 g/g · creatinine, and serum total protein and albumin were 7 g/dl and 4 g/dl, respectively. However, hematuria persisted.
In June 2012, a second renal biopsy was performed to reevaluate renal histology. At the second biopsy, serum creatinine was 1.09 mg/dl with negative urinary protein and urinary red blood cells of 20–29/HPF (Table 2). Total protein and serum albumin were normalized, and serum IgA had decreased from 487 mg/dl at the first biopsy to 297 mg/dl. Four out of twenty-nine glomeruli were globally sclerotic. Other glomeruli exhibited mild mesangial proliferation only (Figure 3A). Tubular atrophy and interstitial fibrosis were present in approximately 30% of the tubulointerstitial area (Figure 3B). IF revealed mild intensity (+) for IgA (Figure 3C) and C3, decreased compared with the first biopsy. On electron microscopy, EDDs in the mesangium were decreased in number and size compared with the first biopsy (Figure 3D). Widening of subendothelial spaces and subendothelial EDDs were still observed segmentally (data not shown).
The pulmonary metastatic lesion showed only slight enlargement, and no new metastatic lesions were identified. However, capecitabine treatment (1800 mg/day) was initiated at the end of October 2012 because CEA gradually increased to 11.4 ng/ml. In December 2012, laboratory data showed no proteinuria, urinary blood cells of 10–15/HPF, serum creatinine of 0.82 mg/dl, and serum IgA of 280 mg/dl. At the final follow-up in July 2013, hematuria first disappeared, and serum creatinine and serum IgA were 0.84 mg/dl and 270 mg/dl, respectively.
Our patient was diagnosed with bevacizumab-induced IgA nephropathy with massive paramesangial deposits because of the following:
neither proteinuria nor hematuria were identified by medical checkups performed prior to bevacizumab treatment
urinary abnormalities first appeared 14 months after bevacizumab initiation
proteinuria disappeared, and hematuria decreased, after bevacizumab cessation and
IgA deposition and paramesangial EDDs were markedly decreased at the second biopsy, 10 months after bevacizumab cessation
TMA, characterized by subendothelial widening with loose granular materials, was also evident in our patient.
Bevacizumab, a recombinant humanized monoclonal antibody for VEGF, inhibits VEGF-induced angiogenesis and tumor growth . Anti-VEGF agents are generally well tolerated, but hypertension and asymptomatic proteinuria are common dose-related adverse effects, frequently occurring together . The incidence of proteinuria ranges from 21%–63% . Although this proteinuria is largely asymptomatic and low-grade, nephrotic-range proteinuria occurs in 1%–2% of bevacizumab-treated patients . VEGF is constitutively expressed on podocytes, and its receptors exist on glomerular capillary endothelial cells . Maintenance of the structure and function of the glomerulus necessitates continuous VEGF production by podocytes. VEGF decrease causes the injury of fenestration of the endothelium, promoting the development of endothelial injuries . These findings suggest that VEGF decrease compromises the glomerular capillary permeability barrier.
Table 3 shows biopsy-documented glomerular disease in 15 bevacizumab-treated patients, including our case [4, 5, 9–14]. The period from bevacizumab initiation to glomerular disease onset ranged from 2 weeks to 15 months. Eight patients exhibited nephrotic syndrome. Nine patients were followed-up after bevacizumab cessation, and all except one experienced decrease or resolution of proteinuria. Histologically, TMA was evident in 12 patients: two in whom it was superimposed on collapsing glomerulopathy or mesangial proliferative glomerulonephritis (GN; our case), one with collapsing glomerulopathy alone, one with cryoglobulinemic GN, and one with focal proliferative immune complex GN (IgM-type). Of the 12 patients with TMA, predominant glomerular IgA deposition was observed in five, including our case [4, 9, 13]. In two of these cases, EDDs were absent. IgA deposition in these patients could be nonspecific; for example, it could be caused by IgA trapped by damaged capillary walls . In one patient with renal cell carcinoma , IgA-dominant glomerular deposition was found at renal biopsy, although no IgA deposition was evident in tissue samples obtained during nephrectomy before bevacizumab treatment. However, EDDs were mainly distributed in widened subendothelial areas associated with mesangial cell interposition. These histological features and the absence of hematuria, which were inconsistent with IgA nephropathy, led to a diagnosis of IgA-predominant immune complex GN rather than IgA nephropathy . In another patient , EDDs were observed mainly in subendothelial areas and segmentally in the mesangium. In our case, the first symptom was hematuria, which was followed by proteinuria. Histologically, IF revealed IgA deposition mainly in the mesangium, along with EDDs and numerous paramesangial hemispherical deposits, which are characteristic of IgA nephropathy . After bevacizumab cessation, these deposits markedly decreased, with the resolution of proteinuria and decreased hematuria. Interestingly, sorafenib, another human monoclonal antibody for VEGF, was reported to cause a rapid deterioration of renal function and a marked increase of proteinuria in pre-exising IgA nephropathy . Chronological changes of our and the reported cases emphasize the close relationship between anti-VEGF effect and IgA nephropathy development and progression. Notably, glomerular and tubulointerstitial sclerotic changes evident at the first biopsy had clearly progressed at the second, associated with increased serum creatinine (0.66 mg/dl at the first biopsy and 1.09 mg/dl at the second), despite the fact that proteinuria had resolved and hematuria had decreased at the second biopsy. This may be because IgA nephropathy remained “active” during the first 6 months after bevacizumab cessation. No decrease in proteinuria and hematuria during the first 6 months supports this possibility.
The mechanisms by which bevacizumab caused IgA nephropathy are unknown. It is easy to eliminate the possibility that IgA immune deposits comprised the bevacizumab–VEGF immune complex, because bevacizumab is a recombinant humanized murine antibody of the IgG1 subclass , and IgG deposition in this case was very mild. One possibility is that circulating IgA immune complexes accumulated in the mesangium and subendothelial areas through capillary walls damaged by bevacizumab. However, the accumulation of IgA immune complexes may depend on factors unique to each patient, such as the amount of circulating IgA immune complexes, the presence or absence of chronic mucosal inflammation, or environmental factors, because not all patients with bevacizumab-induced TMA exhibited glomerular IgA deposition. In our case, serum IgA gradually decreased after bevacizumab cessation (512, 295, 277, and 270 mg/dl at 1, 12, 15, and 25 months after cessation, respectively). To date, no reports describe serum IgA in bevacizumab-induced renal diseases. Although the effect of bevacizumab on the immune system is unclear, further analyses of bevacizumab and serum IgA are warranted, as bevacizumab reportedly affects the permeability of gastroduodenal and intestinal mucosa , which is known to produce mucosal IgA  and to be closely associated with IgA nephropathy development .
In conclusion, this is the first case report that confirmed histologically the development and resolution of IgA nephropathy during and after bevacizumab therapy. Although anti-VEGF effect on the permeability of gastroduodenal and intestinal mucosa might be related to the IgA nephropathy development, further studies and accumulation of cases are warranted to elucidate the exact mechanism.
Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor–in-Chief of this journal.
Electron dense deposits
Vascular endothelial growth factor.
Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004, 25: 581-611. 10.1210/er.2003-0027.
Genentech, Inc.: Avastin® (Bevacizumab) Product Information. 2009, San Francisco, CA: Genentech, Inc.
Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010, 21: 1381-1389. 10.1681/ASN.2010020167.
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008, 358: 1129-1136. 10.1056/NEJMoa0707330.
Frangié C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D: Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007, 8: 177-178. 10.1016/S1470-2045(07)70037-2.
Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2000, 19: 843-850.
Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007, 49: 186-193. 10.1053/j.ajkd.2006.11.039.
Schrijvers BF, Flyvbjerg A, De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004, 65: 2003-2017. 10.1111/j.1523-1755.2004.00621.x.
Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH: Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol. 2007, 3: 287-293. 10.1038/ncpneph0476.
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, Devore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004, 22: 2184-2191. 10.1200/JCO.2004.11.022.
Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005, 23: 792-799. 10.1200/JCO.2005.05.098.
Stokes MB, Erazo MC, D’Agati VD: Glomerular disease related to anti-VEGF therapy. Kidney Int. 2008, 74: 1487-1491. 10.1038/ki.2008.256.
George BA, Zhou XJ, Toto R: Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007, 49: E23-E29. 10.1053/j.ajkd.2006.11.024.
Yeh J, Frieze D, Martins R, Carr L: Clinical utility of bevacizumab for metastatic solid tumors. Ann Pharmacother. 2010, 44: 1010-1015. 10.1345/aph.1M670.
Taguchi T, Von Bassewitz DB, Grundmann E, Takebayashi S: Ultrastructural changes of glomerular basement membrane in IgA nephritis: relationship to hematuria. Ultrastruct Pathol. 1988, 12: 17-26. 10.3109/01913128809048473.
Jonkers IJ, van Buren M: Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin Exp Nephrol. 2009, 13: 397-401. 10.1007/s10157-009-0167-5.
Melichar B, Hyspler R, Kalábová H, Dvorák J, Tichá A, Zadák Z: Gastroduodenal, intestinal and colonic permeability during anticancer therapy. Hepatogastroenterology. 2011, 58: 1193-1199. 10.5754/hge08101.
Cerutti A, Chen K, Chorny A: Immunoglobulin responses at the mucosal interface. Annu Rev Immunol. 2011, 29: 273-293. 10.1146/annurev-immunol-031210-101317.
Pouria S, Barratt J: Secondary IgA nephropathy. Semin Nephrol. 2008, 28: 27-37. 10.1016/j.semnephrol.2007.10.004.
The authors thank Kiyomi Kisu and Shuichi Futatsumori for their excellent technical assistance. This work was presented at the 55th Annual Meeting of the Japanese Society of Nephrology, June 15–17, 2012, Yokohama, Japan.
The authors declare that they have no competing interests.
MY performed the renal biopsy and follow-up of the patient. MY, IN, and JS were involved in drafting the manuscript, and JS carried out final preparation of the manuscript. TS, HS, and SA participated in the discussion of histomorphological and electron microscopy diagnosis. All authors read and approved the final manuscript.
About this article
Cite this article
Yahata, M., Nakaya, I., Sakuma, T. et al. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature. BMC Res Notes 6, 450 (2013). https://doi.org/10.1186/1756-0500-6-450
- Nephrotic syndrome
- Anti-vascular endothelial growth factor therapy
- Immunoglobulin A nephropathy